new warnings about using rosiglitazone (Avandia) in patients with ANY degree of heart failure

September 2006

You'll see new warnings about using rosiglitazone (Avandia) in patients with ANY degree of heart failure.

Physicians already avoid giving rosiglitazone or pioglitazone (Actos) to patients with severe heart failure.

Now there's evidence that rosiglitazone increases cardiac risk in patients with LESS severe heart failure.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote